POWERFUL BLEED
PROTECTION IN PROPHYLAXIS

Doctor Discussion Guide

Use our guide to start the conversation with your Healthcare Provider to see if IDELVION is right for you

IDELVION delivers powerful protection

In the pivotal trial, patients on IDELVION had an average of zero spontaneous and joint bleeds per year.

Zero spontaneous bleeds

Whether dosed every 7 or 14 days in pivotal trials

Extends time between infusions

IDELVION is the only FDA-approved Factor IX therapy that lets some people go up to two weeks between doses—while still maintaining high factor levels and prolonged bleed protection. Explore what 14-day* dosing with IDELVION can do.

 *Once well controlled (1 month without spontaneous bleeding or requiring dose adjustments on a weekly dose of ≤40 IU/kg), people 12 years and older can be transitioned to 14-day dosing.

Up to 14 day dosing with IDELVION

Dosing schedules that
fit your lifestyle

Takes Factor IX to another level in prophylaxis

IDELVION delivered high and sustained Factor IX trough levels—20% with prophylactic use at steady state when dosed every 7 days in adults and adolescents.

  • 13% steady-state trough levels were achieved at 14-day dosing
  • Children younger than 12 years old achieved 13% steady-state trough levels on 7-day dosing§

†Steady state is a consistent and uniform amount of factor in the body from continued use.

‡The average dose for people receiving prophylaxis every 7 days was 37 IU/kg and every 14 days was 73 IU/kg.

§The average dose for children receiving prophylaxis every 7 days was 47 IU/kg.

STEADY-STATE TROUGH LEVELS 20% 7 DAY, 13% 14 DAY WITH PROPHYLACTIC USE‡
Question mark

What are factor trough levels?

Trough levels are the low point factor levels reach shortly before a new dose. Having high factor levels even at the lowest point between doses means you’re better protected even when you’re most vulnerable.

IDELVION extends half-life using
albumin fusion technology

X
You are now leaving the current website.

Do you want to continue?